Publication | Open Access
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
42
Citations
32
References
2023
Year
Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS.
| Year | Citations | |
|---|---|---|
Page 1
Page 1